Lise Lolle Holm

Lise Lolle Holm

Auto-generated profile, based on publicly available information

Lise Lolle Holm

University of Southern Denmark, Dept. of Biochemistry and Molecular Biology , Odense

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2024 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
LHLise L Holm
Lise L Holm
TDThomas Koed Doktor
Thomas Koed Doktor
KFKatharina K Flugt
Katharina K Flugt
UPUlrika S S Petersen
Ulrika S S Petersen
RPRikke Petersen
Rikke Petersen
BABrage Storstein Andresen
Brage Storstein Andresen
It is now widely accepted that aberrant splicing of constitutive exons is often caused by mutations affecting cis-acting splicing regulatory elements (SREs), but there is a misconception that all exons have an equal dependency on SREs and thus a similar vulnerability to aberrant splicing. We demonstrate that some exons are more likely to be affected by exonic splicing mutations (ESMs) due to an inherent vulnerability, which is context dependent and influenced by the strength of exon definition. We have developed VulExMap, a tool which is based on empirical data that can designate whether a constitutive exon is vulnerable. Using VulExMap, we find that only 25% of all exons can be categorized as vulnerable, whereas two-thirds of 359 previously reported ESMs in 75 disease genes are located in vulnerable exons. Because VulExMap analysis is based on empirical data on splicing of exons in their endogenous context, it includes all features important in determining the vulnerability. We believe that VulExMap will be an important tool when assessing the effect of exonic mutations by pinpointing whether they are located in exons vulnerable to ESMs.

14 June 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
LHLise Lolle Holm
Lise Lolle Holm
TDThomas Koed Doktor
Thomas Koed Doktor
KFKatharina Kirkegaard Flugt
Katharina Kirkegaard Flugt
UPUlrika Simone Spangsberg Petersen
Ulrika Simone Spangsberg Petersen
RPRikke Pedersen
Rikke Pedersen
BABrage Storstein Andresen
Brage Storstein Andresen
It is now widely accepted that aberrant splicing of constitutive exons is often caused by mutations affecting cis- acting splicing regulatory elements (SREs), but there is a misconception that all exons have an equal dependency on SREs and thus a similar vulnerability to aberrant splicing. We demonstrate that some exons are more likely to be affected by exonic splicing mutations (ESM) due to an inherent vulnerability, which is context-dependent and influenced by the strength of exon definition. We have developed VulExMap, a tool which based on empirical data that can designate whether a constitutive exon is vulnerable. Using VulExMap, we find that only 27% of all exons can be categorized as vulnerable whereas two-thirds of 332 previously reported ESMs in 71 disease genes are located in vulnerable exons. Because VulExMap analysis is based on empirical data on splicing of exons in their endogenous context, it includes all features important in determining the vulnerability. We believe that VulExMap will be an important tool when assessing the effect of exonic mutations by pinpointing whether they are located in exons vulnerable to ESMs.

7 October 2025 in NAR Molecular Medicine
Verified
Journal Article
Open access
AMAinhoa Martinez-Pizarro
Ainhoa Martinez-Pizarro
SPSara Picó
Sara Picó
MAMar Alvárez
Mar Alvárez
JPJulia Pose-Utrilla
Julia Pose-Utrilla
LHLise Lolle Holm
Lise Lolle Holm
LDLourdes Desviat
Lourdes Desviat
Microexons are enriched in genes linked to autism spectrum disorders (ASDs). We have previously demonstrated decreased inclusion of a neuronal specific 24 bp microexon of the translational regulator CPEB4 in brains of idiopathic ASD cases and that this leads to CPEB4 aggregation and subsequent under-expression of multiple high confidence ASD-risk genes. Furthermore, decreased inclusion of the CPEB4 microexon is also a novel etiological mechanism in schizophrenia (SCZ). In this work, we designed a series of splice switching antisense oligonucleotides (SSOs) targeting the CPEB4 microexon genomic region. SSOs targeting intronic regions near the microexon resulted in a decrease in microexon inclusion in neuroblastoma cells, by blocking hnRNPC binding, mimicking the isoform imbalance observed in ASD. Interestingly, we identified SSOs targeting downstream 3′ splice site of exon 5 that favoured microexon inclusion in a dose-dependent manner and resulted in increased protein levels of AUTS2 and DIRK1A, two high-confidence ASD risk genes, targets of CPEB4, with reduced protein levels in ASD. These results deepen our understanding of the complex splicing regulation of microexons and open new applications of SSOs to treat diseases, such as ASD and SCZ, characterized by altered microexon inclusion.

5 July 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
UPUlrika Simone Spangsberg Petersen
Ulrika Simone Spangsberg Petersen
MDMaja Dembic
Maja Dembic
AMAinhoa Martínez-Pizarro
Ainhoa Martínez-Pizarro
EREva Richard
Eva Richard
LHLise Lolle Holm
Lise Lolle Holm
BABrage Storstein Andresen
Brage Storstein Andresen
Pseudoexons are nonfunctional intronic sequences that can be activated by deep intronic sequence variation. Activation increases pseudoexon inclusion in mRNA and interferes with normal gene expression. The PCCA c.1285-1416A>G variation activates a pseudoexon and causes the severe metabolic disorder, propionic acidemia, by deficiency of the propionyl-CoA carboxylase enzyme encoded by PCCA and PCCB . We characterized this pathogenic pseudoexon activation event in detail and identified hnRNP A1 to be important for normal repression. The PCCA c.1285-1416A>G variation disrupts an hnRNP A1-binding splicing silencer and simultaneously creates a splicing enhancer. We demonstrate that blocking this region of regulation with splice-switching antisense oligonucleotides restores normal splicing and rescues enzyme activity in patient fibroblasts and in a cellular model created by CRISPR gene editing. The PCCA pseudoexon can be exploited as a gene-regulatory switch, as healthy tissues show relatively high levels of inclusion. By blocking inclusion of the non-activated wild type pseudoexon, we increase both PCCA and PCCB protein levels, which increases the activity of the heterododecameric enzyme. Surprisingly, we can increase enzyme activity from residual levels not only in patient fibroblasts harboring PCCA missense variants, but also those harboring PCCB missense variants. This could be a potential treatment strategy for propionic acidemia.